Security
AMGN · Amgen Inc
40 institutional holder(s) · 40 congressional trade(s)
Amgen is one of the largest biotechs, selling drugs across inflammation, oncology, and bone health, including Enbrel and Repatha. It acquired Horizon Therapeutics for its rare-disease drugs. It is held by 11 of 26 tracked funds in the latest quarter and traded by 19 members of Congress in disclosed filings.
Institutional holders
13F
| Fund | Value | Shares |
|---|
| Vanguard Group |
$16.14B | 49,325,180 |
| State Street |
$11.07B | 30,560,537 |
| BlackRock |
$7.11B | 19,634,173 |
| Geode Capital Management |
$5.04B | 13,960,176 |
| BlackRock |
$4.06B | 11,207,860 |
| Morgan Stanley |
$2.39B | 6,588,798 |
| BlackRock |
$2.23B | 6,168,610 |
| Morgan Stanley |
$1.06B | 2,934,664 |
| Vanguard Group |
$1.01B | 3,071,496 |
| Bank of America |
$936.3M | 2,585,478 |
| Fidelity |
$672.8M | 1,858,025 |
| Geode Capital Management |
$628.6M | 1,735,892 |
| BlackRock |
$588.3M | 1,624,606 |
| BlackRock |
$552.6M | 1,526,021 |
| BlackRock |
$444.2M | 1,226,657 |
| BlackRock |
$441.3M | 1,218,771 |
| Morgan Stanley |
$429.8M | 1,187,010 |
| Morgan Stanley |
$428.4M | 1,183,093 |
| Two Sigma Investments |
$408.7M | 1,128,681 |
| BlackRock |
$387.3M | 1,069,587 |
| Vanguard Group |
$384.9M | 1,175,817 |
| Fidelity |
$381.7M | 1,054,125 |
| BlackRock |
$367.5M | 1,014,828 |
| BlackRock |
$359.5M | 992,882 |
| BlackRock |
$355.2M | 980,816 |
| Bank of America |
$348.2M | 961,510 |
| Citadel Advisors |
$332.5M | 918,100 |
| Vanguard Group |
$328.2M | 1,002,862 |
| Morgan Stanley |
$279.2M | 771,113 |
| BlackRock |
$277.6M | 766,464 |
| Bank of America |
$263.7M | 728,313 |
| Bank of America |
$246.4M | 680,472 |
| BlackRock |
$223.8M | 617,927 |
| Citadel Advisors |
$211M | 582,771 |
| Fidelity |
$208M | 574,360 |
| Citadel Advisors |
$180.1M | 497,300 |
| BlackRock |
$178.8M | 493,656 |
| Morgan Stanley |
$169.4M | 467,735 |
| Citadel Advisors |
$126.7M | 350,000 |
| Millennium Management |
$88.1M | 243,300 |
Congressional trades
STOCK Act